Affinage

CARD10

Caspase recruitment domain-containing protein 10 · UniProt Q9BWT7

Length
1032 aa
Mass
115.9 kDa
Annotated
2026-04-28
61 papers in source corpus 30 papers cited in narrative 30 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CARD10 (CARMA3) is a CARD-domain-containing MAGUK scaffold protein that assembles the CARMA3–BCL10–MALT1 (CBM) signalosome to activate canonical NF-κB signaling downstream of G protein-coupled receptors, receptor tyrosine kinases (EGFR), and innate immune sensors (RIG-I/MAVS). CARD10 binds BCL10 via its CARD domain and recruits NEMO/IKKγ and TRAF6 to drive IKK complex polyubiquitination and NF-κB nuclear translocation; in the GPCR context, β-arrestin 2 is required for signalosome assembly, distinguishing it mechanistically from the lymphocyte CARMA1 complex (PMID:11387339, PMID:17438001, PMID:21041303). The pathway is negatively regulated by MALT1-mediated cleavage of CARD10 at R587, by A20 deubiquitylase activity disrupting the CBM–NEMO complex, and by proteasomal degradation of CARD10 following viral infection (PMID:33824280, PMID:18349075, PMID:26947079). Beyond NF-κB scaffolding, CARD10 maintains mitochondrial integrity in endothelial cells, interacts with IP3 receptors to regulate calcium signaling in airway epithelium, and suppresses STAT1 phosphorylation in cardiac fibroblasts (PMID:35831018, PMID:29958012, PMID:41053092).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2001 High

    Identification of CARD10 as a MAGUK-family scaffold that binds BCL10 and MALT1 to activate NF-κB established the existence of a non-lymphocyte CBM signalosome and its core molecular architecture.

    Evidence Co-immunoprecipitation, domain deletion mapping, dominant-negative expression, and NF-κB reporter assays in multiple cell types

    PMID:11259443 PMID:11387339

    Open questions at the time
    • Upstream receptor inputs not yet defined
    • Endogenous stoichiometry and oligomerization state unknown
    • No structural model of the CARD10–BCL10 interface
  2. 2004 High

    Demonstrating that CARD10 physically associates with NEMO/IKKγ in an inducible complex with BCL10 and IKKα/β revealed how the CBM signalosome engages the IKK complex to transmit NF-κB activation signals.

    Evidence Reciprocal co-immunoprecipitation in lymphoid and non-lymphoid cells, dominant-negative NEMO-binding region expression

    PMID:15184390

    Open questions at the time
    • Ubiquitin chain type mediating IKK activation not specified
    • Direct vs. bridged interaction between CARD10 and NEMO not resolved
  3. 2007 High

    Genetic knockout studies established that CARD10 is essential for GPCR-induced NF-κB activation and showed that TRAF6 is recruited to NEMO via CARD10 to catalyze polyubiquitination, defining the pathway from receptor to IKK activation.

    Evidence CARMA3 knockout mice, IKK kinase assays, ubiquitination assays, co-immunoprecipitation, and PKCα epistasis with dominant-negatives in ovarian cancer cells

    PMID:17101977 PMID:17438001 PMID:17724468

    Open questions at the time
    • Direct PKC phosphorylation site on CARD10 not mapped
    • Relationship to alternative ubiquitin ligases (e.g., cIAP1/2) not tested
  4. 2010 High

    Discovery that β-arrestin 2 (not PDK1) mediates CBM signalosome assembly downstream of GPCRs distinguished the CARD10 pathway from the CARMA1-dependent lymphocyte signalosome and linked it to vascular inflammation and atherosclerosis.

    Evidence siRNA knockdown and co-IP in endothelial cells for β-arrestin 2 dependence; Bcl10 knockout mice protected from Ang II-induced atherosclerosis and aortic aneurysms

    PMID:20605784 PMID:21041303

    Open questions at the time
    • β-arrestin 2 binding site on CARD10 not mapped
    • Whether β-arrestin 2 acts as adaptor or conformational activator is unresolved
  5. 2011 High

    Extension of CARD10 function to RTK signaling showed that EGFR activates NF-κB through the CBM signalosome, broadening CARD10's role beyond GPCRs to receptor tyrosine kinase-driven oncogenesis.

    Evidence CARMA3 knockout cells, siRNA, NF-κB reporter, and in vivo tumor xenograft

    PMID:21406399

    Open questions at the time
    • How EGFR signals to CARD10 (direct phosphorylation vs. intermediate PKC) not determined
    • Generality to other RTKs untested
  6. 2015 High

    Conditional knockout of CARD10 in airway epithelial cells demonstrated its non-redundant requirement for allergic airway inflammation, establishing the CBM signalosome as a critical innate epithelial signaling node for proasthmatic mediator production.

    Evidence CARMA3 conditional knockout mice, primary human bronchial epithelial cell siRNA, in vivo allergen challenge models with multiple stimuli

    PMID:26041536

    Open questions at the time
    • Relative contributions of NF-κB versus calcium signaling arms in airway inflammation not dissected
    • Therapeutic window for CARD10 inhibition in asthma not assessed
  7. 2016 High

    Revealing that CARD10 sequesters MAVS from forming high-molecular-weight aggregates to suppress TBK1/IRF3 activation while simultaneously promoting MAVS-dependent NF-κB uncovered a dual regulatory role and a proteasome-dependent degradation switch during antiviral signaling.

    Evidence CARMA3 knockout mice, sucrose gradient sedimentation for MAVS aggregation, proteasome inhibitor experiments, in vivo viral infection

    PMID:26947079

    Open questions at the time
    • Ubiquitin ligase responsible for CARD10 proteasomal targeting not identified
    • Whether CARD10–MAVS interaction is direct or BCL10-bridged not resolved
  8. 2018 Medium

    Identification of CARD10 interaction with IP3 receptors in airway epithelial cells revealed a non-NF-κB function in calcium signaling, expanding the mechanistic repertoire of the scaffold beyond inflammatory transcription.

    Evidence Co-immunoprecipitation of CARMA3–IP3R, intracellular calcium measurement, CARMA3-deficient AEC mice

    PMID:29958012

    Open questions at the time
    • Binding interface between CARD10 and IP3R not mapped
    • Whether calcium regulation requires BCL10/MALT1 or is independent unknown
    • Single-lab finding awaits independent replication
  9. 2021 High

    Discovery that MALT1 cleaves CARD10 at R587 to dampen NF-κB signaling identified the first non-hematopoietic MALT1 substrate and revealed a built-in negative feedback mechanism controlling tumor-promoting inflammation.

    Evidence In vitro MALT1 cleavage assay, R587A mutagenesis, NF-κB reporter, cytokine ELISA, mouse xenograft tumor growth

    PMID:33824280

    Open questions at the time
    • Whether cleavage generates a dominant-negative fragment or simply inactivates CARD10 not fully resolved
    • Kinetics of cleavage relative to signalosome disassembly unknown
  10. 2022 Medium

    Localization of CARD10 to mitochondria in liver sinusoidal endothelial cells and its requirement for mitochondrial integrity independent of NF-κB revealed a previously unsuspected organelle-level function.

    Evidence Subcellular fractionation and co-localization in LSECs, CARMA3 knockout mice, Con A hepatitis model

    PMID:35831018

    Open questions at the time
    • Mitochondrial binding partners and targeting signal not identified
    • Mechanism by which CARD10 preserves mitochondrial integrity unknown
    • Single-lab observation in one cell type
  11. 2025 Medium

    Demonstration that CARD10 physically interacts with STAT1 to suppress its phosphorylation in cardiac fibroblasts uncovered an NF-κB-independent anti-fibrotic mechanism, expanding CARD10's functional scope to JAK-STAT regulation.

    Evidence Co-immunoprecipitation of CARD10–STAT1, CARMA3 knockout mice subjected to TAC and Ang II pressure overload, proteomics

    PMID:41053092

    Open questions at the time
    • Domain on CARD10 mediating STAT1 interaction not mapped
    • Whether STAT1 suppression is direct (sequestration) or involves a phosphatase intermediary unknown
    • Single-lab finding

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of CARD10 signalosome assembly, the identity of the E3 ubiquitin ligase targeting CARD10 for proteasomal degradation during antiviral signaling, whether the mitochondrial and calcium-signaling functions operate through BCL10/MALT1 or represent independent scaffolding modes, and the direct PKC phosphorylation site(s) on CARD10 that activate the signalosome.
  • No high-resolution structure of CARD10 or the CBM signalosome
  • PKC phosphorylation site on CARD10 not mapped in any system
  • Relative physiological importance of NF-κB-dependent vs. -independent functions not compared in a single genetic model

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 7 GO:0098772 molecular function regulator activity 2
Localization
GO:0005829 cytosol 2 GO:0005886 plasma membrane 2 GO:0005739 mitochondrion 1
Pathway
R-HSA-162582 Signal Transduction 10 R-HSA-1643685 Disease 5 R-HSA-168256 Immune System 3 R-HSA-5357801 Programmed Cell Death 1
Partners
BCL10DEPDC7ITPR1MALT1MAVSNEMOSTAT1TRAF6
Complex memberships
CARMA3-BCL10-MALT1 (CBM) signalosome

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 CARD10 (BIMP1) was identified as a novel MAGUK/CARD family member that binds BCL10 and MALT1, forming a ternary complex (with BCL10 bridging BIMP1/MALT1 interaction), and activates NF-κB upstream of IκB kinases; a dominant-negative BIMP1 mutant inhibits NF-κB activation by anti-CD3 ligation, phorbol ester, and PKC expression. Co-immunoprecipitation, dominant-negative mutant expression, NF-κB reporter assays The Journal of biological chemistry High 11387339
2001 CARD10 belongs to the membrane-associated guanylate kinase (MAGUK) family, binds BCL10 via its N-terminal CARD domain, and signals NF-κB activation; proposed to function as a molecular scaffold for assembly of a BCL10 signaling complex at plasma membranes. Co-immunoprecipitation, NF-κB reporter assays, domain deletion analysis The Journal of biological chemistry High 11259443
2004 CARMA3 (CARD10) physically associates with IκB kinase γ/NEMO in lymphoid and non-lymphoid cells and participates in an inducible large molecular complex containing IKKγ/NEMO, BCL10, and IKKα/β; expression of the NEMO-binding region of CARMA3 exerts a dominant-negative effect on BCL10-mediated NF-κB activation. Co-immunoprecipitation, dominant-negative expression, NF-κB reporter assays The Journal of biological chemistry High 15184390
2006 CARMA3/BCL10/MALT1 complex mediates angiotensin II type 1 receptor (GPCR)-induced NF-κB activation in hepatocytes; blocking any of the three proteins via dominant-negative mutants, RNAi, or gene targeting abolishes Ang II-dependent NF-κB activation; pathway activates NF-κB through ubiquitination of IKKγ/NEMO. Dominant-negative mutants, RNAi, Bcl10 knockout mice, ubiquitination assay, NF-κB reporter assays Proceedings of the National Academy of Sciences of the United States of America High 17101977
2007 CARMA3 is required for GPCR-induced NF-κB activation; CARMA3 deficiency impairs GPCR-induced IKK kinase activity (but not IKKα/β phosphorylation); CARMA3 physically associates with NEMO/IKKγ and induces polyubiquitination of a protein associated with NEMO, likely by linking NEMO to TRAF6; TRAF6 deficiency also abrogates GPCR-induced NF-κB activation. CARMA3 knockout mice (gene targeting), Co-immunoprecipitation, IKK kinase assay, ubiquitination assay Genes & development High 17438001
2007 PKCα links LPA receptor signaling to CARMA3 in ovarian cancer cells; LPA stimulation activates PKCα and induces Ras-PKCα interaction; dominant-negative PKCα attenuates LPA-induced NF-κB activation and uPA upregulation; dominant-negative CARMA3 or siRNA knockdown of CARMA3/BCL10/MALT1 diminishes LPA-induced NF-κB activation, uPA upregulation, and invasion. Dominant-negative mutants, siRNA knockdown, NF-κB reporter assays, invasion assays Oncogene High 17724468
2008 The CXCL8/IL-8-CXCR2 axis activates NF-κB and up-regulates VEGF in endothelial cells via the CBM (CARMA3/BCL10/MALT1) complex, independently of HIF1α. Dominant-negative constructs, NF-κB reporter assays, Western blot, siRNA The Journal of biological chemistry Medium 19112107
2008 CARMA3 is specifically expressed in human airway epithelial cells and mediates LPA-induced NF-κB activation and downstream expression of TSLP and CCL20; inhibition of CARMA3 reduces LPA-mediated NF-κB activity and cytokine production in bronchial epithelial cells. siRNA knockdown, NF-κB reporter assays, ELISA, qPCR American journal of respiratory cell and molecular biology Medium 18757306
2008 A20 negatively regulates CARMA3/BCL10/MALT1 signaling by its deubiquitylation activity; A20 perturbs assembly of the CARMA3-BCL10-IKKγ/NEMO complex, suppressing NF-κB activation. Co-immunoprecipitation, deubiquitylation assay, NF-κB reporter assays Journal of cell science Medium 18349075
2009 CXCL12/CXCR4 activates NF-κB through the CARMA3/BCL10/MALT1 (CBM) complex in oral squamous cell carcinoma cells; novel and atypical (but not classical) PKCs activate IKK through CXCR4; CBM complex inhibition significantly decreases SDF-1α-mediated invasion. Lentivirus-based knockdown, Western blot, EMSA, invasion assays International journal of oral science Medium 20695076
2010 CARMA3/BCL10/MALT1 signalosome links PAR-1 (thrombin receptor, a GPCR) activation to IKK complex stimulation in endothelial cells; the CARMA3-containing signalosome relies on β-arrestin 2 (not PDK1) for assembly, distinguishing it from the CARMA1-containing lymphocyte signalosome; thrombin-dependent monocyte-endothelial adhesion requires an intact endothelial CARMA3·BCL10·MALT1 signalosome. siRNA knockdown, Co-immunoprecipitation, NF-κB reporter assays, monocyte-endothelial adhesion assays The Journal of biological chemistry High 21041303
2010 CARMA3/BCL10/MALT1 signalosome mediates angiotensin II type 1 receptor-dependent NF-κB activation in endothelial and vascular smooth muscle cells, driving pro-inflammatory vascular signaling; Bcl10-deficient mice are protected from angiotensin II-dependent atherosclerosis and aortic aneurysms. siRNA knockdown, dominant-negative constructs, Bcl10 knockout mice, in vivo atherosclerosis model The Journal of biological chemistry High 20605784
2011 CARMA3 is required for EGF receptor (RTK)-induced NF-κB activation; CARMA3 deficiency impairs IKK complex activation following EGF stimulation, reducing IκBα phosphorylation and NF-κB activation; CARMA3 and BCL10 contribute to EGFR-associated proliferation, survival, migration, invasion, and tumor growth in vivo. CARMA3 knockout cells, siRNA, NF-κB reporter, in vivo tumor xenograft Cancer research High 21406399
2012 miR-146a directly targets CARD10 and COPS8 mRNA (validated by luciferase assay and Western blot) in gastric cancer cells, inhibiting GPCR-mediated NF-κB activation and reducing LPA-induced cytokine/growth factor expression and monocyte attraction. Luciferase reporter assay, Western blot, qPCR, NF-κB reporter, miR-146a transfection Molecular cancer Medium 22992343
2014 miR-146a induced by LPS directly targets CARD10 in human umbilical vein endothelial cells (validated by Ago2 RIP and luciferase assay); CARD10 knockdown inhibits p65 nuclear translocation and increases angiogenesis, placing CARD10 as a negative regulator of NF-κB-dependent impairment of angiogenesis in a negative feedback loop. Ago2 ribonucleoprotein immunoprecipitation, luciferase reporter assay, siRNA knockdown, p65 nuclear translocation assay, tube formation assay Toxicological sciences Medium 24863965
2014 DEPDC7 (DEP domain-containing protein) binds to CARMA3 as a cellular binding partner; DEPDC7 shRNA-mediated knockdown impairs NF-κB activation following GPCR stimulation (in a CARMA3-dependent but CARMA1-independent manner), identifying DEPDC7 as a CARMA3-specific co-activator in the CBM complex pathway. Co-immunoprecipitation, shRNA knockdown, NF-κB reporter assays PloS one Medium 25541973
2015 CARMA3 promotes lung cancer stemness and metastasis by reducing NME2 levels through an NF-κB/miR-182 pathway; chromatin immunoprecipitation and luciferase assays demonstrate NF-κB-driven miR-182 expression that suppresses NME2, and CARMA3 inversely correlates with NME2 in patient samples. Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA knockdown, in vitro and in vivo metastasis assays American journal of respiratory and critical care medicine Medium 25906011
2015 CARMA3 mediates NF-κB activation and suppresses P38 MAPK signaling in lung cancer cells; CARMA3 knockdown increases P38 phosphorylation while decreasing NF-κB nuclear p65, and P38 inhibitor (SB203580) reverses CARMA3-knockdown-induced migration inhibition and apoptosis, establishing reciprocal regulation between NF-κB and P38 MAPK downstream of CARMA3. siRNA knockdown, P38 inhibitor treatment, Western blot, flow cytometry, NF-κB reporter Experimental and molecular pathology Medium 26526492
2015 CARMA3 depletion in pancreatic cancer cells inhibits EGF-induced NF-κB activation through a Bcl10-dependent mechanism; the effect of CARMA3 depletion on NF-κB signaling is significantly reduced in Bcl10-depleted cells, establishing Bcl10 as essential downstream mediator. siRNA knockdown (CARMA3 and Bcl10), NF-κB reporter assays, Western blot Tumour biology Medium 24633921
2015 CARMA3 is critical for the initiation of allergic airway inflammation via GPCR-induced NF-κB activation in airway epithelial cells; CARMA3-deficient AECs show decreased production of proasthmatic mediators in response to LPA, ATP, Alternaria alternata, and house dust mite; mice with CARMA3-deficient AECs have reduced airway eosinophilia, proinflammatory cytokines, and impaired dendritic cell maturation. CARMA3 conditional knockout mice, siRNA in primary human bronchial epithelial cells, cytokine ELISAs, in vivo allergic airway model Journal of immunology High 26041536
2016 CARMA3 positively regulates MAVS-induced NF-κB activation during RNA virus infection; however, CARMA3 sequesters MAVS from forming high-molecular-weight aggregates, thereby suppressing TBK1/IRF3 activation and type I IFN production; following NF-κB activation, CARMA3 undergoes proteasome-dependent degradation, releasing MAVS to activate IRF3; CARMA3-deficient mice show reduced inflammation and enhanced viral clearance. CARMA3 knockout mice, Co-immunoprecipitation, sucrose gradient sedimentation (MAVS aggregate assay), proteasome inhibitor experiments, in vivo viral infection Cell reports High 26947079
2017 AGTR1 (angiotensin II receptor) overexpression activates NF-κB via the CARMA3/BCL10/MALT1 (CBM) signalosome in breast cancer, driving both ligand-independent and ligand-dependent NF-κB activation, cancer cell proliferation, migration, invasion, and tumor angiogenesis. siRNA knockdown of CBM components, NF-κB reporter assays, in vitro proliferation/migration/invasion assays, endothelial angiogenesis assays Cancer research Medium 29259013
2018 CARD10 is a transcriptional target of CEBPE; CEBPE binds regulatory elements upstream of the murine Card10 locus (shown by ChIP); Card10 expression is significantly reduced in Cebpe knockout mice; silencing Card10 impairs granulopoiesis, demonstrating a role for CARD10 in granulocytic differentiation. ChIP, Cebpe knockout mice, siRNA knockdown in human cell line and murine primary cells, granulopoiesis assays Haematologica Medium 29773596
2018 CARMA3 mediates A. alternata-induced allergic airway inflammation; CARMA3 interacts with inositol 1,4,5-trisphosphate receptors (IP3Rs) in airway epithelial cells, and inhibition of CARMA3 signaling reduces A. alternata-induced intracellular calcium release. Co-immunoprecipitation (CARMA3-IP3R interaction), CARMA3-deficient AEC mice, intracellular calcium measurement, in vivo allergic inflammation model American journal of respiratory cell and molecular biology Medium 29958012
2021 CARD10 is the first identified MALT1 substrate in non-hematopoietic cells; MALT1 cleaves CARD10 at R587, dampening its capacity to activate NF-κB; preventing CARD10 cleavage in lung tumor cells increased basal IL-6 and extracellular matrix components in vitro and led to increased tumor growth in a mouse xenograft model, indicating CARD10 cleavage by MALT1 is a built-in mechanism controlling tumorigenicity. MALT1 cleavage assay (in vitro), site-directed mutagenesis (R587A), NF-κB reporter, cytokine ELISA, mouse xenograft model Oncogenesis High 33824280
2021 CARMA3 promotes CRC motility and cancer stemness via a CARMA3/YAP/Slug signaling axis; CARMA3 activates NF-κB through YAP expression, which upregulates Slug (EMT transcription factor); genetic inhibition of YAP blocks CARMA3-mediated migration/invasion. siRNA/shRNA knockdown, NF-κB reporter, YAP inhibition, in vivo tumor model Cancers Medium 34885061
2022 CARMA3 localizes to mitochondria in liver sinusoidal endothelial cells (LSECs); in Carma3-deficient LSECs, Con A treatment triggers increased mitochondrial damage and cell death, revealing a role for CARMA3 in maintaining mitochondrial integrity independent of its known NF-κB scaffolding function. Carma3 knockout mice, subcellular fractionation/co-localization (mitochondrial localization), in vitro LSEC injury assays, Con A hepatitis model Journal of immunology Medium 35831018
2024 SHH signaling activates the CARD10-BCL10-MALT1 (CBM) complex formation in cardiomyocytes via PKCα; inhibition of PKCα attenuates CBM complex formation; disruption of the CBM complex prevents MALT1 from recruiting TRAF6, which triggers caspase-11-dependent pyroptosis in myocardial ischemia/reperfusion injury. PKCα inhibitor (pharmacological), siRNA knockdown, Co-immunoprecipitation (CBM complex), caspase-11 pyroptosis assay, mouse I/R model European journal of pharmacology Medium 39343081
2024 CARMA3 binds BCL10 and MALT1 to form a signalosome in nucleus pulposus cells; CARMA3 knockdown reduces CARMA3-BCL10-MALT1 signalosome-mediated NF-κB activation, decreasing MMP-3, MMP-13, ADAMTS-5, and caspase-3, and reversing intervertebral disc degeneration pathology. Co-immunoprecipitation (CARMA3-BCL10-MALT1 complex), siRNA knockdown, Western blot, in vivo rat IDD model Inflammation Medium 38607566
2025 CARMA3 suppresses myofibroblast activation by inhibiting STAT1 phosphorylation in cardiac fibroblasts; CARMA3 physically interacts with STAT1 in response to pressure overload; CARMA3-knockout mice show increased STAT1 phosphorylation, exacerbated myofibroblast differentiation, collagen production, and cardiac fibrosis. Co-immunoprecipitation (CARMA3-STAT1 interaction), CARMA3 knockout mice (TAC and Ang II models), proteomic analysis, flow cytometry Cell death discovery Medium 41053092

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. The Journal of biological chemistry 334 19112107
2001 Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction. The Journal of biological chemistry 154 11387339
2006 CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proceedings of the National Academy of Sciences of the United States of America 149 17101977
2001 Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. The Journal of biological chemistry 131 11259443
2007 CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes & development 109 17438001
2012 microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Molecular cancer 86 22992343
2009 CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. International journal of oral science 85 20695076
2011 CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer research 76 21406399
2017 The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer research 74 29259013
2011 Genome-wide association studies in Asians confirm the involvement of ATOH7 and TGFBR3, and further identify CARD10 as a novel locus influencing optic disc area. Human molecular genetics 70 21307088
2010 Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome. The Journal of biological chemistry 69 21041303
2007 Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 67 17724468
2010 The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. The Journal of biological chemistry 66 20605784
2004 Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. The Journal of biological chemistry 62 15184390
2014 MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. Molecular medicine reports 46 24787958
2014 Lipopolysaccharide-induced microRNA-146a targets CARD10 and regulates angiogenesis in human umbilical vein endothelial cells. Toxicological sciences : an official journal of the Society of Toxicology 41 24863965
2008 CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells. American journal of respiratory cell and molecular biology 36 18757306
2015 MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. International journal of oncology 35 26252200
2008 A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB. Journal of cell science 35 18349075
2015 CARMA3 Represses Metastasis Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis. American journal of respiratory and critical care medicine 30 25906011
2012 Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression. PloS one 29 22615840
2012 CARMA3 is overexpressed in colon cancer and regulates NF-κB activity and cyclin D1 expression. Biochemical and biophysical research communications 29 22884800
2019 The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer gene therapy 24 30723269
2018 Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. Journal of inflammation (London, England) 24 30008619
2018 CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis. Frontiers in immunology 24 30158935
2016 CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection. Cell reports 23 26947079
2013 CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 23 23708960
2015 CARMA3 Is Critical for the Initiation of Allergic Airway Inflammation. Journal of immunology (Baltimore, Md. : 1950) 22 26041536
2010 CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseases. World journal of biological chemistry 22 21537470
2019 CARMA3: Scaffold Protein Involved in NF-κB Signaling. Frontiers in immunology 21 30814996
2014 The Dishevelled, EGL-10 and pleckstrin (DEP) domain-containing protein DEPDC7 binds to CARMA2 and CARMA3 proteins, and regulates NF-κB activation. PloS one 21 25541973
2013 CARMA3 is overexpressed in human glioma and promotes cell invasion through MMP9 regulation in A172 cell line. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 21 23893382
2014 Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20 24833094
2018 CARMA3 Mediates Allergic Lung Inflammation in Response to Alternaria alternata. American journal of respiratory cell and molecular biology 18 29958012
2015 CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-кB and suppressing the P38 MAPK signaling pathway. Experimental and molecular pathology 18 26526492
2019 CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate. World journal of gastroenterology 14 31576094
2019 CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway. Molecular medicine reports 14 31939627
2021 CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo. Oncogenesis 13 33824280
2021 MicroRNA‑16‑5p/BIMP1/NF‑κB axis regulates autophagy to exert a tumor‑suppressive effect on bladder cancer. Molecular medicine reports 13 34132358
2014 Clinical significance and biological roles of CARMA3 in human bladder carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 13 24443255
2021 CARMA3 Promotes Colorectal Cancer Cell Motility and Cancer Stemness via YAP-Mediated NF-κB Activation. Cancers 12 34885061
2018 Association of CARD10 rs6000782 and TNF rs1799724 variants with paediatric-onset autoimmune hepatitis. Journal of advanced research 12 30581618
2016 Rare variants in optic disc area gene CARD10 enriched in primary open-angle glaucoma. Molecular genetics & genomic medicine 12 27896285
2020 miR-146a regulates inflammation and development in patients with abdominal aortic aneurysms by targeting CARD10. International angiology : a journal of the International Union of Angiology 11 32138469
2019 Silencing of CARMA3 inhibits bladder cancer cell migration and invasion via deactivating β-catenin signaling pathway. OncoTargets and therapy 10 31496734
2021 Staphylococcus aureus Induces IFN-β Production via a CARMA3-Independent Mechanism. Pathogens (Basel, Switzerland) 9 33806598
2021 CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion. Technology in cancer research & treatment 9 34190011
2015 Lack of association between the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population. BMC research notes 9 26652023
2014 CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 9 24633921
2018 CARD10, a CEBPE target involved in granulocytic differentiation. Haematologica 8 29773596
2018 Analysis of CARD10 and CARD11 somatic mutations in patients with ovarian endometriosis. Oncology letters 8 29928437
2023 CARMA3 Deficiency Aggravates Angiotensin II-Induced Abdominal Aortic Aneurysm Development Interacting Between Endoplasmic Reticulum and Mitochondria. The Canadian journal of cardiology 7 37030515
2022 CARMA3: A potential therapeutic target in non-cancer diseases. Frontiers in immunology 6 36618379
2024 Sonic hedgehog signaling facilitates pyroptosis in mouse heart following ischemia/reperfusion via enhancing the formation of CARD10-BCL10-MALT1 complex. European journal of pharmacology 5 39343081
2021 Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis. Biochemical and biophysical research communications 5 34656852
2024 CARMA3 Drives NF-κB Activation and Promotes Intervertebral Disc Degeneration: Involvement of CARMA3-BCL10-MALT1 Signalosome. Inflammation 3 38607566
2017 Lack of association between CARD10/CARMA3 tag SNPs and psoriasis vulgaris in the southern Chinese population. Genetics and molecular research : GMR 3 28301668
2022 Carma3 Protects from Liver Injury by Preserving Mitochondrial Integrity in Liver Sinusoidal Endothelial Cells. Journal of immunology (Baltimore, Md. : 1950) 2 35831018
2025 The role of CARMA3 in regulating fibrosis to prevent hypertrophic cardiomyopathy. Cell death discovery 1 41053092
2025 Disrupting CARMA3 Signaling with Triptolide Reverses Sorafenib Resistance in Hepatocellular Carcinoma. International journal of medical sciences 0 41209553
2023 [Retracted] MicroRNA‑24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. International journal of oncology 0 37083072